Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the activity of EPO906 administered once every 3 weeks to patients with advanced NSCLC
Critère d'inclusion
- Non-small cell lung cancer (NSCLC) - patients with inoperable stage IIIb or IV NSCLC have a very poor prognosis, with overall survival of 4-8 months